
Merck
MKKGY | OTC
$32.78
-$0.29 (-0.88%)
At close: Nov 16, 2026, 3:53 PM ET
$32.73
-$0.05 (-0.15%)
After-hours:
Nov 16, 2026, 3:37 PM ET
Merck Company Profile
Company profile explainedCompany Profile
Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Science segment provides an extensive portfolio of tools, chemicals, and equipment essential for academic research laboratories, biotech firms, pharmaceutical manufacturers, and the broader industrial sector. This division also furnishes drug developers with specialized process development expertise and advanced technologies, such as continuous bioprocessing, alongside a variety of testing kits, reagents, and associated services. Furthermore, it delivers analytical solutions for environmental monitoring (air, water, and soil) and products designed to evaluate nutritional content and detect quality deviations. The Healthcare segment focuses on the discovery, development, manufacturing, and commercialization of prescription drugs and biopharmaceuticals. Its therapeutic areas encompass oncology, neurology and immunology, fertility, endocrinology, cardiovascular conditions, diabetes, thyroid disorders, and multiple sclerosis. This segment also markets general medicines and integrates medical technology, including injection devices and disease monitoring software. The Electronics segment supplies critical materials to the semiconductor and display industries. It also specializes in surface design solutions, offering comprehensive delivery systems, services, and innovative surface products, which include cosmetic ingredients, effect pigments, and various functional applications. Beyond its internal operations, Merck KGaA actively pursues strategic collaborations. This includes in-licensing agreements, such as with Debiopharm International SA for drug candidates targeting head and neck cancer; with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for treatments against metastatic colorectal cancer; and with Abbisko Therapeutics Co. Ltd. for therapies for tenosynovial giant cell tumor. The company also holds a license and collaboration agreement dedicated to identifying two targeted protein degraders for vital oncogenic proteins. Established in 1668, Merck KGaA boasts a long and distinguished history and is headquartered in Darmstadt, Germany. The company functions as a subsidiary under the umbrella of E. Merck KG.
Key Executives
| Name | Position |
|---|---|
| Benjamin Hein | Member of Management Board & CEO of Electronics Business Sector |
| Danny Pinhas Bar-Zohar | Member of the Executive Board & Chief Executive Officer of Healthcare |
| Jean Charles Wirth | Member of the Executive Board & Chief Executive Officer Life Science |
| Kai Beckmann | CEO & Chair of Management Board |
| Helene von Roeder | Chief Financial Officer & Member of Executive Board |
| Khadija Ben Hammada | Member of the Executive Board & Chief People Officer |
| Axel Lober | Head of Global Communications |
| Florian Schraeder | Head of Investor Relations |
| Frank Gotthardt | Head of Corporate & Government Relations - Europe |
| Marc Horn | Head of Life Science Controlling |
Merck

| Country | Germany |
| IPO Date | Nov 16, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 62,461 |
| CEO | Kai Beckmann |
Contact Details
Frankfurter Strasse 250 Darmstadt,
HE 64293 Germany
Stock Details
| Ticker Symbol | MKKGY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 589339209 |
| ISIN Number | US5893392093 |
| SIC Code | n/a |
Recent News
- 4 days ago / seekingalpha.comMerck KGaA (MKKGY) Q3 2026 Earnings Call Transcript
- 29 days ago / wsj.comGermany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
- 3 months ago / seekingalpha.comMerck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
- 3 months ago / zacks.comMerck KGaA (MKKGY) Misses Q2 Earnings Estimates
- 4 months ago / businesswire.comEvinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
- 4 months ago / zacks.comMerck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
- 4 months ago / zacks.comAre Investors Undervaluing Merck KGaA (MKKGY) Right Now?
- 5 months ago / zacks.comMerck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
- 5 months ago / benzinga.comMerck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
- 5 months ago / barrons.comGermany's Merck Is Buying Bio-Techne for $11.3 Billion
Add to Watchlist
Select watchlists to add or remove MKKGY